Optimal conditions for quantification of IRF4 mRNA and protein as a correlative biomarker in clinical cancer studies

Joshua D. Hartman, Silvia Vicenzi, Alexander Tong, Lara C. Avsharian, Ashni A. Vora, Caitlin Costello, Ida Deichaite, Leslie CrewsJournal of Translational Medicine 2026 · DOI

TL;DR

This study identifies optimal pre-analytical conditions for reliably quantifying IRF4 mRNA and protein in peripheral blood, crucial for its use as a biomarker in hematological malignancies like multiple myeloma. The findings highlight Sodium Citrate tubes as the superior choice for sample collection, ensuring analyte stability for up to 48 hours post-collection, which is vital for multi-site clinical trials.

What Problem Does This Paper Address?

The development of targeted therapies for diseases like multiple myeloma (MM) hinges on the ability to accurately measure specific biomarkers. IRF4, a transcription factor frequently dysregulated in MM and other hematological cancers, has emerged as a promising biomarker. However, its utility in clinical settings, particularly for patient selection and monitoring treatment response, is hampered by a lack of standardized protocols for sample collection and processing. This paper addresses the critical need to establish optimal pre-analytical conditions (tube type, processing time, cell isolation) to ensure the reliable and stable quantification of IRF4 mRNA and protein from peripheral blood samples, which is essential for the success of ongoing and future clinical trials involving IRF4-targeting agents.

Methods

The researchers employed a multi-faceted approach to evaluate IRF4 stability under various pre-analytical conditions.

  • Sample Collection: Whole blood was collected from healthy donors in three different tube types: EDTA, Paxgene ccfDNA, and Sodium Citrate.
  • Processing Intervals: Samples were processed either immediately (24 hours post-collection) or after a delay (48 hours post-collection) to simulate real-world clinical trial logistics.
  • Cell Isolation: Peripheral blood mononuclear cells (PBMCs) were isolated, and then further fractionated into CD3+ T lymphocytes, CD14+ monocytes, and CD19+ B lymphocytes using magnetic bead separation.
  • RNA Quantification: Quantitative Real-Time PCR (qRT-PCR) was used to measure IRF4 mRNA levels. The study also investigated the stability of different housekeeping genes (ACTB, HSPA5, ATF4) to identify the most reliable reference for normalization.
  • Protein Quantification: Intranuclear IRF4 protein levels were assessed using flow cytometry, along with the stability of various immune cell surface markers.
  • Statistical Analysis: Data were analyzed using standard statistical methods, including one-way ANOVA with post-hoc Tukey-Kramer tests, to identify significant differences between conditions.

Datasets

The study utilized peripheral blood samples from 5 healthy donors. These samples were commercially sourced from AllCells. No new benchmark datasets were introduced.

Key Insights and Ideas

  • Sodium Citrate Reigns Supreme: The most significant finding is the clear superiority of Sodium Citrate tubes for preserving both IRF4 mRNA and protein stability over a 48-hour period. This is a crucial takeaway for clinical trial design.
  • Protein is More Robust: IRF4 protein appears to be slightly more stable than its mRNA counterpart under variable processing delays, offering a potential advantage for certain analytical workflows.
  • Housekeeping Gene Matters: The choice of housekeeping gene for qRT-PCR is critical. ACTB, a common reference, showed instability, whereas HSPA5 emerged as a more reliable option, particularly when paired with Sodium Citrate tubes. ATF4 was also stable but was excluded due to potential regulatory interactions with IRF4.
  • Cellular Heterogeneity: IRF4 protein expression varied across immune cell subsets, with higher levels observed in CD14+ (monocytes) and CD19+ (B cells) compared to CD3+ (T cells). This highlights the importance of considering cell populations when interpreting IRF4 levels.
  • Practical Implications for Multi-Site Trials: The 48-hour processing window is highly relevant for multi-site studies where sample shipment and processing delays are common. The findings provide actionable guidance to ensure data integrity.

Key Results

  • RNA Stability: Sodium Citrate tubes maintained the most stable IRF4 mRNA levels across both 24 and 48-hour processing intervals, with consistent raw Cq values. EDTA and Paxgene tubes showed more variability.
  • Protein Stability: Intranuclear IRF4 protein levels were remarkably stable across all tested tube types and processing intervals, indicating robust protein detection regardless of these pre-analytical variables.
  • Cell Surface Antigen Stability: Sodium Citrate tubes also demonstrated the highest stability of immune cell surface antigens over the 24-48 hour processing delays.
  • Cell Viability and Yield: While EDTA tubes offered higher initial blood volumes and thus higher raw cell counts, Sodium Citrate tubes provided comparable adjusted cell counts per mL and good RNA yields, especially considering their smaller collection volume. Paxgene tubes generally showed lower RNA yields.

Limitations and Future Work

  • Healthy Donors Only: The study was conducted using samples from healthy donors. Future work should validate these findings in patient populations, particularly those with hematological malignancies where IRF4 is dysregulated.
  • Limited Tube Types: While three common tube types were tested, other specialized collection tubes might exist.
  • Plasma/Serum Analysis: Sodium Citrate tubes, while optimal for cellular analytes, are less ideal for plasma or serum analysis. The authors suggest using a separate serum-separator tube for such endpoints.
  • Tissue Types: The recommendations are specific to peripheral blood. Further research is needed to determine optimal conditions for IRF4 quantification in other tissue types, such as bone marrow.
  • Heparin Tubes Excluded: Heparin tubes were excluded due to potential interference with downstream PCR applications, a known limitation that could be explored in future studies.

Summary updated

Abstract

The transcription factor interferon-regulatory factor-4 (IRF4) has recently been highlighted as a valuable biomarker due to its common dysregulation and association with poor prognoses in hematological malignancies such as multiple myeloma (MM). With several clinical programs for the inhibition of IRF4 currently in development, determination of the optimal sample collection conditions and quantification methods will facilitate optimal selection of patients for these treatments, along with enabling robust monitoring of their molecular responses to IRF4 inhibitory agents over time. Using peripheral blood samples from healthy donors, we evaluated IRF4 mRNA and protein stability across a range of pre-analytical conditions including blood collection tube type (comparing EDTA, Paxgene ccfDNA, and Na Citrate), sample processing interval (24 to 48 hours after sample collection), and cell population isolated (total mononuclear cells, CD3+ T lymphocytes, CD14+ monocytes, and CD19+ B lymphocytes). We sought to further determine the extent to which post-processing variables such as cell yield, RNA yield, and housekeeping gene (ACTB versus HSPA5 and ATF4) selection may influence measurements of IRF4 mRNA and protein abundance. RNA and protein quantification endpoints included qRT-PCR and intranuclear flow cytometric analyses, respectively, to characterize the cell surface and intracellular molecular signatures. In qRT-PCR biomarker studies, we found that human IRF4 expression was detectable in all cell fractions (PBMCs, CD19+ B cells and CD3+ T cells) evaluated and tube types tested (Na Citrate, EDTA, Paxgene ccfDNA). However, transcript stability of hIRF4 and the well-established reference gene β-actin (ACTB), as inferred from raw quantification cycle (Cq) values, varied substantially across tube types and between processing delay time points. mRNA levels of IRF4 along with an alternate, MM-optimized, reference gene, HSPA5, were determined to exhibit optimal stability in samples collected in Na Citrate preservative tubes. This tube type also offered the highest stability of immune cell surface antigens across 24–48-hour processing delays. Intranuclear IRF4 protein levels were remarkably stable in all cell populations tested across all tube types, with the highest relative expression in CD14+ and CD19+ fractions, and lowest in CD3+ fractions, in this cohort of healthy donors. Overall, Na Citrate tubes maintained the stability of IRF4 mRNA and protein expression even after sample processing intervals of up to 48 hours post-collection. Furthermore, IRF4 protein appears to be slightly more stable than mRNA after variable processing delays, but both analytes are expected to be detectable and relatively stable in clinical samples, thus enabling reliable analysis of IRF4 as a molecular biomarker in clinical samples collected from multiple sites and shipped to a central laboratory.
BibTeX
@article{hartman2026optimal,
  author = {Joshua D. Hartman and Silvia Vicenzi and Alexander Tong and Lara C. Avsharian and Ashni A. Vora and Caitlin Costello and Ida Deichaite and Leslie Crews},
  title = {{Optimal conditions for quantification of IRF4 mRNA and protein as a correlative biomarker in clinical cancer studies}},
  journal = {Journal of Translational Medicine},
  year = {2026},
  doi = {10.1186/s12967-026-07803-0},
}
Figure